These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12154036)

  • 1. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
    Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
    Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
    Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
    Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: novel classes of histone deacetylase inhibitors.
    Moradei O; Leit S; Zhou N; Fréchette S; Paquin I; Raeppel S; Gaudette F; Bouchain G; Woo SH; Vaisburg A; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Li Z; Rahil J; MacLeod AR; Besterman JM; Delorme D
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4048-52. PubMed ID: 16713259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of potential antitumor agents. Synthesis and biological evaluation of a new set of sulfonamide derivatives as histone deacetylase inhibitors.
    Bouchain G; Leit S; Frechette S; Khalil EA; Lavoie R; Moradei O; Woo SH; Fournel M; Yan PT; Kalita A; Trachy-Bourget MC; Beaulieu C; Li Z; Robert MF; MacLeod AR; Besterman JM; Delorme D
    J Med Chem; 2003 Feb; 46(5):820-30. PubMed ID: 12593661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YM753, a novel histone deacetylase inhibitor, exhibits antitumor activity with selective, sustained accumulation of acetylated histones in tumors in the WiDr xenograft model.
    Shindoh N; Mori M; Terada Y; Oda K; Amino N; Kita A; Taniguchi M; Sohda KY; Nagai K; Sowa Y; Masuoka Y; Orita M; Sasamata M; Matsushime H; Furuichi K; Sakai T
    Int J Oncol; 2008 Mar; 32(3):545-55. PubMed ID: 18292931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin.
    Han JW; Ahn SH; Park SH; Wang SY; Bae GU; Seo DW; Kwon HK; Hong S; Lee HY; Lee YW; Lee HW
    Cancer Res; 2000 Nov; 60(21):6068-74. PubMed ID: 11085529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Regulation of histone acetylation on the expression of cell cycle-associated genes in human colon cancer cell lines].
    Chen YX; Fang JY; Lu J; Qiu DK
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):312-7. PubMed ID: 15059516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells.
    Ahn MY; Jung JH; Na YJ; Kim HS
    Gynecol Oncol; 2008 Jan; 108(1):27-33. PubMed ID: 17920664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
    Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
    Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
    Jaboin J; Wild J; Hamidi H; Khanna C; Kim CJ; Robey R; Bates SE; Thiele CJ
    Cancer Res; 2002 Nov; 62(21):6108-15. PubMed ID: 12414635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
    Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
    Lin YC; Lin JH; Chou CW; Chang YF; Yeh SH; Chen CC
    Cancer Res; 2008 Apr; 68(7):2375-83. PubMed ID: 18381445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines.
    Ryu JK; Lee WJ; Lee KH; Hwang JH; Kim YT; Yoon YB; Kim CY
    Cancer Lett; 2006 Jun; 237(1):143-54. PubMed ID: 16009488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel inhibitors of human histone deacetylases: design, synthesis, enzyme inhibition, and cancer cell growth inhibition of SAHA-based non-hydroxamates.
    Suzuki T; Nagano Y; Kouketsu A; Matsuura A; Maruyama S; Kurotaki M; Nakagawa H; Miyata N
    J Med Chem; 2005 Feb; 48(4):1019-32. PubMed ID: 15715470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase.
    Kim YB; Lee KH; Sugita K; Yoshida M; Horinouchi S
    Oncogene; 1999 Apr; 18(15):2461-70. PubMed ID: 10229197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
    Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
    Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
    Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
    Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation.
    Camphausen K; Scott T; Sproull M; Tofilon PJ
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6066-71. PubMed ID: 15447991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-(Heteroarylaminomethyl)-N-(2-aminophenyl)-benzamides and their analogs as a novel class of histone deacetylase inhibitors.
    Fréchette S; Leit S; Woo SH; Lapointe G; Jeannotte G; Moradei O; Paquin I; Bouchain G; Raeppel S; Gaudette F; Zhou N; Vaisburg A; Fournel M; Yan PT; Trachy-Bourget MC; Kalita A; Robert MF; Lu A; Rahil J; Robert Macleod A; Besterman JM; Li Z; Delorme D
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1502-6. PubMed ID: 18207391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent in vivo anti-breast cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice.
    Joung KE; Min KN; An JY; Kim DK; Kong G; Sheen YY
    Cancer Res; 2006 May; 66(10):5394-402. PubMed ID: 16707467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.